肝疾患治療薬の世界市場：2015〜2019年

肝疾患には、肝炎、肝癌、非アルコール性脂肪肝、肝硬変などがあります。肝炎は最大のセグメントであり、中でもC型肝炎が最大で最速で増加しています。ウイルス感染やアルコール、肥満、糖尿病などが肝疾患の原因となります。世界の肝疾患治療薬市場は2014〜2019年にかけCAGR15.61%で拡大すると予測されています。

当レポートでは、世界の肝疾患治療薬市場の現況と2015〜2019年の成長見通しについて調査し、市場規模、収益動向、製品別、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 疾患概要

• 肝炎
• 肝癌
• 肝硬変
• 非アルコール性脂肪肝

第6章 市場環境

第7章 疾患別セグメンテーション

• 肝炎
• 肝硬変
• 肝癌
• 非アルコール性脂肪肝

第8章 世界の肝炎治療薬市場

• A型肝炎市場
• B型肝炎市場
• C型肝炎市場

第9章 世界の肝癌治療薬市場

第10章 世界の非アルコール性脂肪肝治療薬市場

第11章 世界の肝硬変治療薬市場

第12章 分子別市場セグメンテーション

• 生物製剤
• 小分子

第13章 地域別セグメンテーション

• 南北アメリカ
• 欧州・中東・アフリカ
• アジア太平洋地域

第14章 市場促進因子

第15章 市場促進因子の影響

第16章 市場の課題

第17章 促進因子と課題の影響

第18章 市場動向

第19章 ベンダー環境

• 競合シナリオ
• 市場シェア分析：2014年
• その他の注目すべきベンダー

第20章 主要ベンダー分析

• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck

第21章 付録

図表

• Exhibit 01: Product offerings
• Exhibit 02: Hepatitis: Mode of transmission and incubation period
• Exhibit 03: Various modes of transmission of hepatitis B viral infection
• Exhibit 04: Various modes of transmission of hepatitis C viral infection
• Exhibit 05: Worldwide endemicity of hepatitis A virus infection
• Exhibit 06: Worldwide endemicity of hepatitis B virus infection
• Exhibit 07: Prevalence of hepatitis B in US 2005-2013
• Exhibit 08: Prevalence of hepatitis C across regions
• Exhibit 09: Antibodies indicating hepatitis
• Exhibit 10: Tests for viral proteins and genetic material
• Exhibit 11: Screening tests for hepatitis C infection
• Exhibit 12: Recommended dosages and schedules of hepatitis A vaccines
• Exhibit 13: Global liver diseases therapeutics market 2014-2019 ($ billions)
• Exhibit 14: Five forces analysis
• Exhibit 15: Global liver diseases therapeutics market by disease 2014
• Exhibit 16: Global hepatitis therapeutics market 2014-2019 ($ millions)
• Exhibit 17: Global hepatitis A therapeutics market 2014-2019 ($ millions)
• Exhibit 18: Global hepatitis B therapeutics market 2014-2019 ($ millions)
• Exhibit 19: Global hepatitis C therapeutics market 2014-2019 ($ millions)
• Exhibit 20: Global hepatitis therapeutics market by type 2014
• Exhibit 21: Global liver cancer therapeutics market 2014-2019 ($ millions)
• Exhibit 22: Global liver cancer therapeutics market: Challenges and drivers
• Exhibit 23: Global nonalcoholic fatty liver disease therapeutics market 2014-2019 ($ millions)
• Exhibit 24: Global nonalcoholic fatty liver disease therapeutics market: Challenges and drivers
• Exhibit 25: Global liver cirrhosis therapeutics market 2014-2019 ($ millions)
• Exhibit 26: Global liver cirrhosis therapeutics market: Challenges and drivers
• Exhibit 27: Global liver diseases therapeutics market by geography 2014
• Exhibit 28: Liver diseases therapeutics market in Americas ($ billions)
• Exhibit 29: Liver diseases therapeutics market in EMEA ($ billions)
• Exhibit 30: Liver diseases therapeutics market in APAC ($ billions)
• Exhibit 31: Impact of drivers
• Exhibit 32: Impact of drivers and challenges
• Exhibit 33: Johnson & Johnson: Business segmentation

About liver diseases

Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment. The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early. This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs.

Technavio's analysts forecast the global liver diseases therapeutics market to grow at a CAGR of 15.61% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases.

Based on disease indication, the market is segmented as follows:

• Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis)
• Liver cirrhosis
• Liver cancer
• Hepatitis (Hepatitis A, B, and C)

This report includes a discussion of the market in the following three regions:

• Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil

• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE

• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India.

Technavio's report, Global Liver Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the global liver diseases therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

• Americas
• APAC
• EMEA

Key vendors

• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck

Other Prominent Vendors

• AbbVie
• Achillion Pharmaceuticals
• Advinus
• Angion Biomedica
• AstraZeneca
• Bayer
• BiOrion
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celsion
• Conatus
• Digna Biotech
• Dynavax Technologies
• Eli Lilly
• Galectin Therapeutics
• Genfit
• GenKyoTex
• Isis Pharmaceuticals
• Janssen Pharmaceuticals
• Kaketsuken
• La Jolla Pharmaceutical
• LG Life Sciences
• Mitsubishi Tanabe Pharma
• Nitto Denko
• Novartis
• Onyx Pharmaceuticals
• Phenex Pharmaceuticals
• Promedior
• Promethera Biosciences
• ProMetic Life Sciences
• Raptor Pharmaceuticals
• Shenzhen Kangtai Biological Products
• TCM Biotech
• Tobira Therapeutics
• VBL Therapeutics
• Verva Pharmaceuticals
• Virobay
• Zafgen

Key market driver

• Increased prevalence of liver diseases
• For a full, detailed list, view our report

Key market challenge

• Multiple patent expiries
• For a full, detailed list, view our report

Key market trend

• Growing public awareness
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of the report

Market overview

• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

• Hepatitis
• Liver cancer
• Liver cirrhosis
• Nonalcoholic fatty liver disease

PART 06: Market landscape

• Global liver diseases therapeutics market

PART 07: Market segmentation by disease

• Hepatitis
• Liver cirrhosis
• Liver cancer
• Nonalcoholic fatty liver disease

PART 08: Global hepatitis therapeutics market

• Global hepatitis A therapeutics market
• Global hepatitis B therapeutics market
• Global hepatitis C therapeutics market

PART 09: Global liver cancer therapeutics market

PART 10: Global nonalcoholic fatty liver disease therapeutics market

PART 11: Global liver cirrhosis therapeutics market

PART 12: Market segmentation by type of molecule

• Biologics
• Small molecules

PART 13: Geographical segmentation

• Liver diseases therapeutics market in Americas
• Liver diseases therapeutics market in EMEA
• Liver diseases therapeutics market in APAC

PART 14: Market drivers

PART 15: Impact of drivers

PART 16: Market challenges

PART 17: Impact of drivers and challenges

PART 18: Market trends

PART 19: Vendor landscape

• Competitive scenario
• Market share analysis 2014
• Other and future prominent vendors

PART 20: Key vendor analysis

• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck

PART 21: Appendix

• List of abbreviations
• Explore Technavio